Yi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yi Xu has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Yunfu Cui
Department of Pancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, China
42 shared publications Kaiming Leng
Department of Hepatopancreatobiliary Surgery, Qingdao Municipal Hospital, Qingdao University, Qingdao, PR China
21 shared publicationsDaolin Ji
18 shared publicationsPengcheng Kang
Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China
18 shared publications- Judy Wai Ping Yam
Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; State Key Laboratory of Liver Research (The University of Hong Kong), Hong Kong, China; Materials Innovation Institute for Life Sciences and Energy (MILES), HKU-SIRI, Shenzhen, China
17 shared publications Liang Yu
Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China
16 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 49873
Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study
Background:Type 2 diabetes mellitus (T2DM) is a major public health challenge. This study aimed to explore the molecular mechanisms underlying the effects of semaglutide on lipid metabolism in visceral white adipose tissue in a mouse model of T2DM.Methods:Male C57BL/6J mice were given a normal diet, a high-fat diet with streptozotocin, or a high-fat diet with semaglutide. Blood samples, liver tissue, and adipose tissue were collected for analysis. Serum adipokines, inflammatory cytokines, liver function, and lipid profiles were assessed. White adipose tissue and liver sections were processed for hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC) staining for the macrophage marker F4/80. High-throughput targeted lipidomic analysis of epididymal white adipose tissue from these animals was performed using liquid chromatography-tandem mass spectrometry to characterize changes in lipid composition and function. Furthermore, the expression of genes related to adipokines, inflammation, and lipid metabolism in epididymal adipose tissue was determined by reverse transcription-quantitative PCR (RT-qPCR).Results:Semaglutide significantly improved systemic metabolism in mice with T2DM, as demonstrated by reductions in body weight, blood glucose, serum lipid levels, and insulin resistance indices homeostasis model assessment of insulin resistance (HOMA-IR) and adipose tissue insulin resistance index (Adipo-IR). Serum Leptin, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) levels were downregulated, while Adiponectin levels were elevated. Histological analysis revealed that semaglutide effectively reduced adipocyte size, suppressed macrophage infiltration in adipose tissue, and decreased liver lipid accumulation. Targeted lipidomic profiling identified 24 lipid subclasses, of which 50 lipid molecules were significantly changed after semaglutide treatment. Enrichment analysis identified 15 metabolic pathways, with glycerophospholipid metabolism being the most prominently affected. RT-qPCR results confirmed that semaglutide altered the expression of key genes involved in glycerolipid, glycerophospholipid, fatty acid, and cholesterol metabolism.Conclusions:These results shed light on the comprehensive remodeling of semaglutide in improving lipid metabolism in epididymal white adipose tissue mice with T2DM.
- 22 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 49873
Open AccessSemaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study
Background:Type 2 diabetes mellitus (T2DM) is a major public health challenge. This study aimed to explore the molecular mechanisms underlying the effects of semaglutide on lipid metabolism in visceral white adipose tissue in a mouse model of T2DM.Methods:Male C57BL/6J mice were given a normal diet, a high-fat diet with streptozotocin, or a high-fat diet with semaglutide. Blood samples, liver tissue, and adipose tissue were collected for analysis. Serum adipokines, inflammatory cytokines, liver function, and lipid profiles were assessed. White adipose tissue and liver sections were processed for hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC) staining for the macrophage marker F4/80. High-throughput targeted lipidomic analysis of epididymal white adipose tissue from these animals was performed using liquid chromatography-tandem mass spectrometry to characterize changes in lipid composition and function. Furthermore, the expression of genes related to adipokines, inflammation, and lipid metabolism in epididymal adipose tissue was determined by reverse transcription-quantitative PCR (RT-qPCR).Results:Semaglutide significantly improved systemic metabolism in mice with T2DM, as demonstrated by reductions in body weight, blood glucose, serum lipid levels, and insulin resistance indices homeostasis model assessment of insulin resistance (HOMA-IR) and adipose tissue insulin resistance index (Adipo-IR). Serum Leptin, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) levels were downregulated, while Adiponectin levels were elevated. Histological analysis revealed that semaglutide effectively reduced adipocyte size, suppressed macrophage infiltration in adipose tissue, and decreased liver lipid accumulation. Targeted lipidomic profiling identified 24 lipid subclasses, of which 50 lipid molecules were significantly changed after semaglutide treatment. Enrichment analysis identified 15 metabolic pathways, with glycerophospholipid metabolism being the most prominently affected. RT-qPCR results confirmed that semaglutide altered the expression of key genes involved in glycerolipid, glycerophospholipid, fatty acid, and cholesterol metabolism.Conclusions:These results shed light on the comprehensive remodeling of semaglutide in improving lipid metabolism in epididymal white adipose tissue mice with T2DM.
- Open Access
- 5 June 2026
- Published by Springer Nature in MedScience
- Vol. 20 (3) , 496-514
PDRG1 induced by SP1 facilitates the proliferation and metastasis of hepatocellular carcinoma by activating the Wnt/β-catenin pathway
Hepatocellular carcinoma (HCC) remains a lethal malignancy with limited therapeutic targets. P53 and DNA damage-regulated gene 1 (PDRG1) has emerged as an oncogene in multiple cancers, yet its role and regulatory mechanism in HCC remain unclear. Here, we demonstrated that PDRG1 expression was significantly upregulated in HCC tissues compared to normal liver, correlating with advanced tumor stage, higher grade, and poor patient survival. Functionally, PDRG1 knockdown suppressed HCC cell proliferation, migration, and invasion in vitro and inhibited tumor growth and lung metastasis in vivo , whereas PDRG1 overexpression exerted opposite effects. Mechanistically, PDRG1 activated Wnt/β-catenin signaling, elevating levels of β-catenin, c-Myc, and phosphorylated GSK-3β, and the oncogenic effects of PDRG1 were reversed by the Wnt pathway inhibitor XAV939. Furthermore, transcription factor Specificity Protein 1 (SP1) bound directly to the PDRG1 promoter at the E3 site (–1927 to–1917) and activated its transcription. The pro-tumor effects of SP1 were rescued by PDRG1 silencing, indicating that SP1 acts through PDRG1. Collectively, our study identifies SP1 as an upstream transcriptional activator of PDRG1 and defines the SP1/PDRG1/Wnt/β-catenin axis as a key regulatory pathway promoting HCC progression, suggesting its potential as a prognostic biomarker and therapeutic target.
- 5 June 2026
- Published by Springer Nature in MedScience
- Vol. 20 (3) , 496-514
Open AccessPDRG1 induced by SP1 facilitates the proliferation and metastasis of hepatocellular carcinoma by activating the Wnt/β-catenin pathway
Hepatocellular carcinoma (HCC) remains a lethal malignancy with limited therapeutic targets. P53 and DNA damage-regulated gene 1 (PDRG1) has emerged as an oncogene in multiple cancers, yet its role and regulatory mechanism in HCC remain unclear. Here, we demonstrated that PDRG1 expression was significantly upregulated in HCC tissues compared to normal liver, correlating with advanced tumor stage, higher grade, and poor patient survival. Functionally, PDRG1 knockdown suppressed HCC cell proliferation, migration, and invasion in vitro and inhibited tumor growth and lung metastasis in vivo , whereas PDRG1 overexpression exerted opposite effects. Mechanistically, PDRG1 activated Wnt/β-catenin signaling, elevating levels of β-catenin, c-Myc, and phosphorylated GSK-3β, and the oncogenic effects of PDRG1 were reversed by the Wnt pathway inhibitor XAV939. Furthermore, transcription factor Specificity Protein 1 (SP1) bound directly to the PDRG1 promoter at the E3 site (–1927 to–1917) and activated its transcription. The pro-tumor effects of SP1 were rescued by PDRG1 silencing, indicating that SP1 acts through PDRG1. Collectively, our study identifies SP1 as an upstream transcriptional activator of PDRG1 and defines the SP1/PDRG1/Wnt/β-catenin axis as a key regulatory pathway promoting HCC progression, suggesting its potential as a prognostic biomarker and therapeutic target.
- Open Access
- 21 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
TTLL12 counteracts BPOZ-2 to stabilize eEF1A1 and promote hepatocarcinogenesis
Tubulin tyrosine ligase-like enzyme-12 (TTLL-12), belonging to the TTLL family, holds a crucial position in posttranslational tubulin modifications implicated in cancer development, making it a potential target for anti-tumor therapy. However, the precise mechanisms of TTLL12 in HCC remain inadequately elucidated. In this study, we found markedly elevated expression of TTLL12 in HCC tissues compared to their adjacent normal counterparts, which is strongly linked to an unfavorable prognosis. Functional assays demonstrated that knockdown of TTLL12 significantly suppressed HCC cell proliferation, whereas overexpression of TTLL12 promoted oncogenic behaviors. In vivo models further confirmed that TTLL12 enhances tumor growth, as indicated by larger tumors in TTLL12-overexpressing cells compared to vector controls. Mechanistically, TTLL12 suppressed ubiquitin-proteasome-mediated degradation of eEF1A1 via competing with Bood POZ-containing gene type 2 (BPOZ-2), which typically recruits eEF1A1 to CULLIN (CUL3), and ultimately results in an enhancement of cancer cell proliferation. Our analyses underscore the oncogenic potential of TTLL12 in hepatocarcinogenesis by safeguarding eEF1A1 from BPOZ-2- mediated degradation, introducing a novel therapeutic target for combating HCC.
- 21 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessTTLL12 counteracts BPOZ-2 to stabilize eEF1A1 and promote hepatocarcinogenesis
Tubulin tyrosine ligase-like enzyme-12 (TTLL-12), belonging to the TTLL family, holds a crucial position in posttranslational tubulin modifications implicated in cancer development, making it a potential target for anti-tumor therapy. However, the precise mechanisms of TTLL12 in HCC remain inadequately elucidated. In this study, we found markedly elevated expression of TTLL12 in HCC tissues compared to their adjacent normal counterparts, which is strongly linked to an unfavorable prognosis. Functional assays demonstrated that knockdown of TTLL12 significantly suppressed HCC cell proliferation, whereas overexpression of TTLL12 promoted oncogenic behaviors. In vivo models further confirmed that TTLL12 enhances tumor growth, as indicated by larger tumors in TTLL12-overexpressing cells compared to vector controls. Mechanistically, TTLL12 suppressed ubiquitin-proteasome-mediated degradation of eEF1A1 via competing with Bood POZ-containing gene type 2 (BPOZ-2), which typically recruits eEF1A1 to CULLIN (CUL3), and ultimately results in an enhancement of cancer cell proliferation. Our analyses underscore the oncogenic potential of TTLL12 in hepatocarcinogenesis by safeguarding eEF1A1 from BPOZ-2- mediated degradation, introducing a novel therapeutic target for combating HCC.
- Open Access
- 30 March 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Recent advances in machine learning-enhanced extracellular vesicle omics for oncology
Extracellular vesicles (EVs) are nanoscale, membrane-bound particles that carry nucleic acids, proteins, metabolites, and lipids. Their omics profiles can
- 30 March 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessRecent advances in machine learning-enhanced extracellular vesicle omics for oncology
Extracellular vesicles (EVs) are nanoscale, membrane-bound particles that carry nucleic acids, proteins, metabolites, and lipids. Their omics profiles can
- Open Access
- 27 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (25) , e16546
Oral Streptococcus salivarius Couples Neutrophil IRGM1 Signaling to NET Formation and Colorectal Cancer Metastasis
Under certain conditions, components of the oral microbiota have been detected in the gastrointestinal tract, implicating oral microbial communities in intestinal immune regulation. However, the mechanisms by which oral microbiota contribute to metastasis at distant organs remain unclear. Here, we demonstrate that the oral bacterium Streptococcus salivarius promotes metastasis of colorectal cancer (CRC) by inducing neutrophil extracellular trap (NET) formation. Mechanistically, S. salivarius induces formation of an IRGM1‐IQGAP1 complex in neutrophils, in which immune‐related GTPase M1 (IRGM1) interacts with IQ motif‐containing GTPase‐activating protein 1 (IQGAP1), leading to activation of Wnt5a signaling and subsequent engagement of the PI3K/AKT pathway, thereby promoting NET formation. Functional validation experiments show that conditional deletion of IRGM1 or pharmacological inhibition of downstream signaling using XAV‐939 markedly attenuates S. salivarius‐ induced NET formation, indicating the requirement of this pathway in the metastatic process. Furthermore, clinical sample analyses reveal that S. salivarius is significantly enriched in the tongue coating and feces of patients with CRC and is elevated within the tumor microenvironment. Together, these findings identify IRGM1‐IQGAP1‐mediated Wnt5a‐PI3K/AKT signaling as a mechanistic link between oral microbiota and neutrophil‐driven immune responses in cancer metastasis.
- 27 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (25) , e16546
Open AccessOral Streptococcus salivarius Couples Neutrophil IRGM1 Signaling to NET Formation and Colorectal Cancer Metastasis
Under certain conditions, components of the oral microbiota have been detected in the gastrointestinal tract, implicating oral microbial communities in intestinal immune regulation. However, the mechanisms by which oral microbiota contribute to metastasis at distant organs remain unclear. Here, we demonstrate that the oral bacterium Streptococcus salivarius promotes metastasis of colorectal cancer (CRC) by inducing neutrophil extracellular trap (NET) formation. Mechanistically, S. salivarius induces formation of an IRGM1‐IQGAP1 complex in neutrophils, in which immune‐related GTPase M1 (IRGM1) interacts with IQ motif‐containing GTPase‐activating protein 1 (IQGAP1), leading to activation of Wnt5a signaling and subsequent engagement of the PI3K/AKT pathway, thereby promoting NET formation. Functional validation experiments show that conditional deletion of IRGM1 or pharmacological inhibition of downstream signaling using XAV‐939 markedly attenuates S. salivarius‐ induced NET formation, indicating the requirement of this pathway in the metastatic process. Furthermore, clinical sample analyses reveal that S. salivarius is significantly enriched in the tongue coating and feces of patients with CRC and is elevated within the tumor microenvironment. Together, these findings identify IRGM1‐IQGAP1‐mediated Wnt5a‐PI3K/AKT signaling as a mechanistic link between oral microbiota and neutrophil‐driven immune responses in cancer metastasis.
- Open Access
- 18 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (42) , e08613
Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis
Clathrin light chain B (CLTB) is one of the three light chain subunits of the clathrin complex. This study aims to elucidate the role of CLTB in the pathogenesis of hepatocellular carcinoma (HCC) and its clinical implications. Clinical and bioinformatic analyses reveal marked CLTB overexpression in HCC tissues. Genetic silencing of CLTB suppresses HCC cell proliferation, migration, and invasion, whereas its overexpression exacerbates malignant phenotypes. Mechanistically, CLTB activates NF‐κB signaling to upregulate PCNA clamp‐associated factor (PCLAF), thereby promoting small extracellular vesicle (sEV) uptake. Given that clathrin‐mediated endocytosis is the key mechanism for sEV uptake, this study further investigated the functional implications of CLTB‐enriched sEVs in tumor vascular remodeling. sEV‐CLTB promotes endothelial angiogenesis, disrupts vascular integrity, and induces pulmonary vascular leakage by binding SH3 domain‐containing kinase‐binding protein 1 (SH3KBP1) and then inhibiting SH3KBP1 ubiquitination degradation. In patient‐derived xenograft (PDX) models, combined therapy of clathrin inhibitor (chlorpromazine) or SH3KBP1 silencing with sorafenib suppresses tumor growth and reduces microvascular density. This study demonstrates that CLTB promotes HCC progression through the NF‐κB–PCLAF signaling axis and sEV‐mediated vascular remodeling, providing a mechanistic foundation for developing combination therapies targeting CLTB.
- 18 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (42) , e08613
Open AccessClathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis
Clathrin light chain B (CLTB) is one of the three light chain subunits of the clathrin complex. This study aims to elucidate the role of CLTB in the pathogenesis of hepatocellular carcinoma (HCC) and its clinical implications. Clinical and bioinformatic analyses reveal marked CLTB overexpression in HCC tissues. Genetic silencing of CLTB suppresses HCC cell proliferation, migration, and invasion, whereas its overexpression exacerbates malignant phenotypes. Mechanistically, CLTB activates NF‐κB signaling to upregulate PCNA clamp‐associated factor (PCLAF), thereby promoting small extracellular vesicle (sEV) uptake. Given that clathrin‐mediated endocytosis is the key mechanism for sEV uptake, this study further investigated the functional implications of CLTB‐enriched sEVs in tumor vascular remodeling. sEV‐CLTB promotes endothelial angiogenesis, disrupts vascular integrity, and induces pulmonary vascular leakage by binding SH3 domain‐containing kinase‐binding protein 1 (SH3KBP1) and then inhibiting SH3KBP1 ubiquitination degradation. In patient‐derived xenograft (PDX) models, combined therapy of clathrin inhibitor (chlorpromazine) or SH3KBP1 silencing with sorafenib suppresses tumor growth and reduces microvascular density. This study demonstrates that CLTB promotes HCC progression through the NF‐κB–PCLAF signaling axis and sEV‐mediated vascular remodeling, providing a mechanistic foundation for developing combination therapies targeting CLTB.
- Open Access
- 31 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1613560
The functional roles of deoxyelephantopin potential target circTNPO3 in regulating pancreatic cancer malignant phenotype and gemcitabine chemoresistance via miR-188-5p/CDCA3/TRAF2-mediated remodeling of NF-κB signaling pathway
Background: Pancreatic cancer (PC) has been one of the most severe digestive system malignant tumor with poor prognosis that threatens human health. Chemotherapy is essential for patients with advanced PC, but unfortunately the curative effect is limited by chemoresistance. CircTNPO3, a recently discovered circular RNA (circRNA), has been indicated to be associated with multi-types of tumors. However, the function and mechanism of circTNPO3 in regulating PC malignant phenotype and chemoresistance still remain obscure.Methods: qRT-PCR and ISH were used to analyze circTNPO3 expression in PC cells and pathological specimens. The subcellular localization of circTNPO3 was visualized through nucleoplasmic RNA separation and FISH assays. The effect of cicTNPO3 on PC cell proliferation, migration and invasion was assessed using EdU, colony formation, wound healing and Transwell assays respectively. Cell apoptosis was detected using ELISA, AO/EB, Hoechst 33342 and flow cytometry assays. The binding potential between circTNPO3, miR-188-5p and CDCA3 was verified by Ago2-RIP, RNA pull down and dual-luciferase reporter assays. The relationship between CDCA3, TRAF2 and NF-κB-p65 was analyzed using Pearson correlation, and the expression was detected using immunoblotting. The nucleus translocation of p65 was evaluated using IF assay. The effect of circTNPO3 on PC growth and metastasis was analyzed using subcutaneous and lung metastatic tumor models in vitro. Deoxyelephantopin, a small molecule extract from traditional Chinese medicine, was applied to evaluate the potential of circTNPO3 as therapeutic target.Results: CircTNPO3 was aberrantly highly expressed in PC cells and tissues, and negatively associated with patient prognosis and gemcitabine chemotherapy sensitivity. Functionally, silencing circTNPO3 attenuated the malignant phenotypes and chemoresistance of PC in vitro and in vivo, conversely, facilitated by circTNPO3 overexpression. Mechanically, cytoplasmic circTNPO3 functioned as a sponge of miR-188-5p, and partially alleviated the effect of miR-188-5p on downstream molecules, which further upregulate the CDCA3 and TRAF2 expression and NF-κB activity, finally promoted PC progression and chemoresistance. More innovatively, the potential of circTNPO3 as a novel diagnostic biomarker and therapeutic target for PC was primarily validated in present study.Conclusion: CircTNPO3 acted as an oncogenic and chemoresistant gene in PC, mechanically through targeting miR-188-5p and regulating CDCA3, TRAF2 and NF-κB signaling pathway.
- 31 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1613560
Open AccessThe functional roles of deoxyelephantopin potential target circTNPO3 in regulating pancreatic cancer malignant phenotype and gemcitabine chemoresistance via miR-188-5p/CDCA3/TRAF2-mediated remodeling of NF-κB signaling pathway
Background: Pancreatic cancer (PC) has been one of the most severe digestive system malignant tumor with poor prognosis that threatens human health. Chemotherapy is essential for patients with advanced PC, but unfortunately the curative effect is limited by chemoresistance. CircTNPO3, a recently discovered circular RNA (circRNA), has been indicated to be associated with multi-types of tumors. However, the function and mechanism of circTNPO3 in regulating PC malignant phenotype and chemoresistance still remain obscure.Methods: qRT-PCR and ISH were used to analyze circTNPO3 expression in PC cells and pathological specimens. The subcellular localization of circTNPO3 was visualized through nucleoplasmic RNA separation and FISH assays. The effect of cicTNPO3 on PC cell proliferation, migration and invasion was assessed using EdU, colony formation, wound healing and Transwell assays respectively. Cell apoptosis was detected using ELISA, AO/EB, Hoechst 33342 and flow cytometry assays. The binding potential between circTNPO3, miR-188-5p and CDCA3 was verified by Ago2-RIP, RNA pull down and dual-luciferase reporter assays. The relationship between CDCA3, TRAF2 and NF-κB-p65 was analyzed using Pearson correlation, and the expression was detected using immunoblotting. The nucleus translocation of p65 was evaluated using IF assay. The effect of circTNPO3 on PC growth and metastasis was analyzed using subcutaneous and lung metastatic tumor models in vitro. Deoxyelephantopin, a small molecule extract from traditional Chinese medicine, was applied to evaluate the potential of circTNPO3 as therapeutic target.Results: CircTNPO3 was aberrantly highly expressed in PC cells and tissues, and negatively associated with patient prognosis and gemcitabine chemotherapy sensitivity. Functionally, silencing circTNPO3 attenuated the malignant phenotypes and chemoresistance of PC in vitro and in vivo, conversely, facilitated by circTNPO3 overexpression. Mechanically, cytoplasmic circTNPO3 functioned as a sponge of miR-188-5p, and partially alleviated the effect of miR-188-5p on downstream molecules, which further upregulate the CDCA3 and TRAF2 expression and NF-κB activity, finally promoted PC progression and chemoresistance. More innovatively, the potential of circTNPO3 as a novel diagnostic biomarker and therapeutic target for PC was primarily validated in present study.Conclusion: CircTNPO3 acted as an oncogenic and chemoresistant gene in PC, mechanically through targeting miR-188-5p and regulating CDCA3, TRAF2 and NF-κB signaling pathway.
- Open Access
- 14 January 2025
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Unraveling the Role of the Wnt Pathway in Hepatocellular Carcinoma: From Molecular Mechanisms to Therapeutic Implications
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on understanding its pathogenesis and developing treatments.The Wnt signaling pathway, a complex and evolutionarily conserved signal transduction system, has been extensively studied in the genesis and treatment of several malignant tumors. Recent investigations suggest that the pathogenesis of HCC may be significantly influenced by dysregulated Wnt/β-catenin signaling. This article aimed to examine the pathway that controls Wnt signaling in HCC and its mechanisms. In addition, we highlighted the role of this pathway in HCC etiology and targeted treatment.
- 14 January 2025
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessUnraveling the Role of the Wnt Pathway in Hepatocellular Carcinoma: From Molecular Mechanisms to Therapeutic Implications
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on understanding its pathogenesis and developing treatments.The Wnt signaling pathway, a complex and evolutionarily conserved signal transduction system, has been extensively studied in the genesis and treatment of several malignant tumors. Recent investigations suggest that the pathogenesis of HCC may be significantly influenced by dysregulated Wnt/β-catenin signaling. This article aimed to examine the pathway that controls Wnt signaling in HCC and its mechanisms. In addition, we highlighted the role of this pathway in HCC etiology and targeted treatment.
- Open Access
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (11) , 3207-3229
Exosomal Non-Coding RNAs in Pancreatic Cancer: From Mechanisms to Clinical Applications
Pancreatic cancer (PC) is an extremely aggressive cancer of the digestive system with insidious onset and the lack of effective biomarkers, resulting in late-stage diagnosis and poor prognosis. Exosomal non-coding RNAs (ncRNAs) are key mediators of intercellular communication that drive PC initiation and advancement. By modulating gene expression, they impact tumor microenvironment (TME) remodeling, proliferation, migration, apoptosis, and immune evasion. Critically, exosomal ncRNAs serve as promising biomarkers for early diagnosis and prognostic assessment. This review summarizes the current research achievements regarding exosomal ncRNAs in PC, systematically elaborating on their roles in tumor occurrence, metastasis, chemoresistance and the TME. Furthermore, by integrating the potential of exosomal ncRNAs in the diagnosis, treatment and prognosis of PC and by highlighting the challenges and future directions, this review aims to offer novel insights for future research and clinical translation of exosomal ncRNAs in PC.
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (11) , 3207-3229
Open AccessExosomal Non-Coding RNAs in Pancreatic Cancer: From Mechanisms to Clinical Applications
Pancreatic cancer (PC) is an extremely aggressive cancer of the digestive system with insidious onset and the lack of effective biomarkers, resulting in late-stage diagnosis and poor prognosis. Exosomal non-coding RNAs (ncRNAs) are key mediators of intercellular communication that drive PC initiation and advancement. By modulating gene expression, they impact tumor microenvironment (TME) remodeling, proliferation, migration, apoptosis, and immune evasion. Critically, exosomal ncRNAs serve as promising biomarkers for early diagnosis and prognostic assessment. This review summarizes the current research achievements regarding exosomal ncRNAs in PC, systematically elaborating on their roles in tumor occurrence, metastasis, chemoresistance and the TME. Furthermore, by integrating the potential of exosomal ncRNAs in the diagnosis, treatment and prognosis of PC and by highlighting the challenges and future directions, this review aims to offer novel insights for future research and clinical translation of exosomal ncRNAs in PC.
- Open Access
- 28 November 2024
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Exosome-mediated Crosstalk in the Tumor Immune Microenvironment: Critical Drivers of Hepatocellular Carcinoma Progression
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the fourth leading cause of cancer-related mortality worldwide. Despite advancements in therapeutic strategies, mortality rates for HCC remain high. The tumor immune microenvironment (TIME) plays a vital role in HCC progression by influencing tumor cell survival and growth. Recent studies highlight the essential role of exosomes in mediating intercellular communication within the TIME, particularly in interactions among tumor cells, immune cells, and fibroblasts. These interactions drive critical aspects of tumor development, including immune escape, angiogenesis, drug resistance, and metastasis. A detailed understanding of the molecular mechanisms by which exosomes modulate the TIME is essential for developing targeted therapies. This review systematically evaluated the roles and regulatory mechanisms of exosomes within the TIME of HCC, examining the impact of both HCC-derived and non-HCC-derived exosomes on various cellular components within the TIME. It emphasized their regulatory effects on cell phenotypes and functions, as well as their roles in HCC progression. The review also explored the potential applications of exosome-based immunotherapies, offering new insights into improving therapeutic strategies for HCC.
- 28 November 2024
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessExosome-mediated Crosstalk in the Tumor Immune Microenvironment: Critical Drivers of Hepatocellular Carcinoma Progression
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the fourth leading cause of cancer-related mortality worldwide. Despite advancements in therapeutic strategies, mortality rates for HCC remain high. The tumor immune microenvironment (TIME) plays a vital role in HCC progression by influencing tumor cell survival and growth. Recent studies highlight the essential role of exosomes in mediating intercellular communication within the TIME, particularly in interactions among tumor cells, immune cells, and fibroblasts. These interactions drive critical aspects of tumor development, including immune escape, angiogenesis, drug resistance, and metastasis. A detailed understanding of the molecular mechanisms by which exosomes modulate the TIME is essential for developing targeted therapies. This review systematically evaluated the roles and regulatory mechanisms of exosomes within the TIME of HCC, examining the impact of both HCC-derived and non-HCC-derived exosomes on various cellular components within the TIME. It emphasized their regulatory effects on cell phenotypes and functions, as well as their roles in HCC progression. The review also explored the potential applications of exosome-based immunotherapies, offering new insights into improving therapeutic strategies for HCC.